NPPA Revised MRPs for 1,364 Anti-Cancer Formulations Effective from 9 November 2026
Quick note
Below is the official summary and the reference document preview. Use “Open PDF” for full screen view.
Schedule a Call Back
Summary
The National Pharmaceutical Pricing Authority (NPPA) has implemented the new MRPs for anti-cancer drugs with effect from 9 November 2026. This move comes after an order made on 17 October 2026, which restricts the margin of trade in 137 identified non-scheduled anti-cancer drugs to 30%. This is meant to narrow the gap between the cost of production and the price paid by the patient for these drugs.
As per the Ministry of Chemicals and Fertilizers, 85 drug firms had submitted revised MRPs for 1,364 formulations of 121 medicines up to 8 November 2026. Out of these, 679 brands had offered a cut in prices above 50%, with the maximum cut being 96.45%. These revisions can save the consumer about 3,540.38 crore rupees annually.
The revised anti-cancer medicine prices are now applicable, making it important for manufacturers, distributors, chemists, hospitals and medical institutions to review their pricing practices. The order also contains specific requirements concerning MRP calculations, price reporting, publication of revised prices and continued medicine supply.
For companies, this NPPA anti-cancer drug price revision 2026 raises a practical drug pricing compliance question: which formulations are covered, and what changes must be reflected in their current price records?
NPPA Anti-Cancer Drug Price Revision 2026: Key Details
The new pricing rules were introduced under the Trade Margin Rationalisation (TMR), which is an instrument used by NPPA to regulate excess margin in the pharmaceutical supply chain.
| Particulars | Details |
| Issuing authority | National Pharmaceutical Pricing Authority (NPPA) |
| Governing department | Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers |
| Original order | S.O. 5690(E), 17 October 2026 |
| Legal basis | Paragraph 19, Drugs (Prices Control) Order, 2013 |
| Effective date | 9 November 2026 |
| Identified drugs | 137 non-scheduled anti-cancer drugs |
| Maximum trade margin | 30% |
| Companies reporting revised MRPs as of 8 November | 85 |
| Reported revised MRPs | 1,364 formulations covering 121 drugs |
| Brands reporting price cuts above 50% | 679 |
| Highest reported reduction | 96.45% |
| Estimated annual consumer savings | 3,540.38 crore rupees |
Regulatory Framework for Anti-Cancer Drug Pricing in India
Medicine prices in India are regulated under the Drugs (Prices Control) Order, 2013 (DPCO), which operates under the Essential Commodities Act, 1955. The NPPA implements the pricing provisions, monitors medicine prices and examines violations of applicable price controls.
Medicines have been categorized as scheduled and non-scheduled formulations under DPCO 2013. The scheduled formulations have been regulated through the First Schedule, and they are controlled by the ceiling-price system. The non-scheduled formulations have been regulated through Paragraph 20, which controls the rise in their MRP. However, Paragraph 19 gives an exception in case of emergency.
The latest decision uses Paragraph 19 to regulate the trade margins of 137 identified non-scheduled anti-cancer drugs. These drugs were recommended by an expert committee constituted under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.
It is not the first time that an initiative like this has been taken. In 2019, the NPPA had launched Trade Margin Rationalisation of 42 anti-cancer drugs. The October 2026 directive has expanded this initiative to include more drugs, including some patented ones, as per applicable legal exemptions.
For businesses reviewing DPCO 2013 compliance requirements, the first step is to check whether a medicine falls within the notified list before applying the new pricing method.
Why Has NPPA Reduced the Prices of Anti-Cancer Medicines?
Cancer treatment often involves expensive medicines, particularly targeted therapies, immunotherapy drugs and medicines required during repeated treatment cycles. For patients and their families, the cost of medication can account for a substantial part of the overall treatment expense.
One concern identified by the government was the large difference between the price at which pharmaceutical companies supplied certain medicines and the Maximum Retail Price charged to patients. High trade margins within the distribution and retail chain could increase the final cost considerably, even when the manufacturer's selling price was much lower.
The NPPA order seeks to address this difference by restricting trade margins instead of applying the same price reduction to every medicine. It is also intended to preserve medicine availability. Manufacturers must comply with the order's production and supply requirements so that lower prices do not lead to avoidable shortages.
The anti-cancer drug price reduction in India therefore varies by medicine, brand and formulation rather than following a single percentage for every product.
What Has Changed Under the NPPA Anti-Cancer Drug Pricing Order?
The October 2026 notice mandates that manufacturers of medicines under covered non-scheduled formulations should compute their MRPs using the trade margin formula. If the MRP of any medicine is higher than the computed value, then the manufacturer should lower the price.
The new prices shall be effective from 9th November 2026 onwards. Thereafter, no retailer or hospital pharmacy would be permitted to charge more than the new MRP of the product. The manufacturer must adhere to the instructions contained in the notification.
It must be mentioned that the order does not require the sale of all medicines at a certain discount rate. While some of the medicines have witnessed more than 50% discount, some have experienced less change in prices. In case the current MRP is less than the maximum calculated, then that must be followed.
The order remains effective until further directions. Annual price increases permitted under Paragraph 20(1) of DPCO 2013 remain subject to continued compliance with the maximum trade margin of 30%.
What Is the 30% Trade Margin Cap on Anti-Cancer Medicines?
The term trade margin is used to describe the difference between the cost of selling a drug by the manufacturer to the stockist/distributor and the price of selling it to the customer, without including the Goods and Services Tax (GST).
For the identified anti-cancer drugs, NPPA has limited this margin to 30% of the permitted pre-GST retail price. This is different from a rule requiring every manufacturer to reduce the previous MRP by 30%.
The notification uses the Price to Stockist or Price to Distributor (PTS/PTD) to calculate the maximum permissible MRP.
The prescribed formula is:
Maximum permissible MRP = PTS/PTD × [1 + 30 ÷ (100 − 30)] + Applicable GST
The maximum allowable pre-GST MRP can be determined by dividing the relevant PTS/PTD by 0.70. The GST can only be charged where it has either been paid or is payable to the government.
In the case of existing drugs, the computation normally involves the average PTS/PTD for March 2026. However, the notification provides an alternative method when there were no sales of the drug in that month.
The distinction matters for pharmaceutical manufacturers because an incorrect calculation could result in an MRP higher than the permitted limit, even if the business intended to follow the 30% rule.
An NPPA trade margin rationalisation compliance review should use the applicable PTS/PTD data and the correct GST treatment, not an assumed discount from the previous retail price.
Which Anti-Cancer Drugs and Formulations Are Covered?
This order lists 137 non-scheduled anti-cancer medicines. The order is applicable to all formulations that contain any of these 137 non-scheduled anti-cancer medicines in any combination, form, strength or route of administration.
The notified list includes medicines used for several types of cancer and certain treatments associated with cancer care. Some important examples are:
- Pembrolizumab and Durvalumab: Immunotherapy medicines used for specified cancer treatments.
- Bevacizumab: Used in the treatment of certain cancers, including colorectal, lung, ovarian and cervical cancers.
- Osimertinib: Used in specified types of non-small-cell lung cancer.
- Denosumab: Used for certain cancer-related bone conditions and other approved indications.
- Pegfilgrastim: Used to reduce the risk of neutropenia associated with certain chemotherapy treatments.
- Abiraterone acetate: Used in the treatment of specified forms of prostate cancer.
- Pemetrexed: Used in certain lung cancer treatment regimens.
The complete list is provided in Table B of NPPA Order S.O. 5690(E). Businesses should check the notified drug name and formulation details before deciding whether a particular product is covered.
A single drug may be marketed under several brands, strengths and pack sizes. This explains why the reported number of formulations is much higher than the number of identified drugs.
According to the government's 7 November announcement, approximately 10–15 of the identified drugs had not yet been launched in India. The trade-margin restriction will apply to those identified drugs when they enter the market, subject to the order's requirements.
For the NPPA anti-cancer drug price list 2026, the brand name, strength and pack size are important because the revised MRP of cancer medicines can differ between formulations.
Old vs Revised MRP of Anti-Cancer Medicines in India
The official price comparisons show how widely the reductions differ between brands. Some medicines have seen particularly large cuts, while others have experienced more moderate changes.
The following table contains selected prices updated on 7 November 2026.
| Formulation | Brand | Company | Old MRP | Revised MRP |
| Bevacizumab 100 mg injection | Bryxta | Zydus Lifesciences | 25,995.00 rupees | 3,318.00 rupees |
| Denosumab 60 mg injection | DenOsteoRel | Reliance Life Sciences | 24,955.00 rupees | 6,240.00 rupees |
| Abiraterone acetate 250 mg tablet | ABIRONE | Arvincare Pharma | 41,250.00 rupees | 3,218.23 rupees |
| Pegfilgrastim 6 mg injection | PEG FILTERO | Hetero Healthcare | 9,093.00 rupees | 1,631.00 rupees |
| Azacitidine 100 mg injection | AzatiRel | Reliance Life Sciences | 7,790.00 rupees | 1,397.00 rupees |
| Pemetrexed 500 mg vial | ReliTrexed | Reliance Life Sciences | 9,977.00 rupees | 1,113.00 rupees |
| Pertuzumab 420 mg injection | LUPIHER 2 | Lupin | 83,520.00 rupees | 37,358.35 rupees |
The figures show the effect of the revised pricing method. For example, the reported MRP of Bryxta fell from 25,995 rupees to 3,318 rupees, while ReliTrexed fell from 9,977 rupees to 1,113 rupees.
Nevertheless, the reduction is not supposed to be considered as a regular reduction for all medicines that contain the same ingredient, since the price arrangement for each brand or formulation can vary from another.
For the complete and updated list, consumers and businesses can refer to the NPPA revised anti-cancer drug prices.
NPPA Compliance Requirements for Pharmaceutical Manufacturers
The revised MRP notification creates specific responsibilities for pharmaceutical manufacturers dealing in the identified medicines. The most important requirement is to calculate the permitted MRP accurately and ensure that the revised price is communicated throughout the supply chain.
Manufacturers must also submit the prescribed information to NPPA and the concerned State Drug Controller. The original order required revised price information in Annexure I within seven days of publication in the Official Gazette, even where the calculation did not result in a change to the existing MRP.
The main requirements include:
- Recalculate the applicable MRP: Use the prescribed PTS/PTD data and trade-margin formula for each covered formulation.
- Submit revised price information: Provide the prescribed Annexure I information to NPPA and the concerned State Drug Controller within the notified period.
- Issue and submit price lists: Follow the applicable Form V and Integrated Pharmaceutical Database Management System (IPDMS) requirements under DPCO 2013.
- Communicate revised prices: Inform dealers and retailers, publish the required newspaper notices and make revised MRP details available on the company's website.
- Maintain supporting records: Preserve relevant pricing information, submissions, stock details and evidence of communication required by the order.
- Maintain medicine supply: Follow the notification's restrictions on reducing production or discontinuing covered formulations.
Since the notification is dated 17 October 2026, the seven-day reporting period had already elapsed by the time the new rates took effect on 9 November. Businesses that have not yet complied with the notification need to evaluate their position right away.
Important conditions for MRP calculations
The notification contains several conditions that manufacturers need to consider before finalising their prices.
Where a covered formulation had no sales during March 2026, the PTS/PTD is calculated using the relevant sales data for April 2025 to March 2026. Government sales are excluded from this calculation.
Medicines supplied free under qualifying Patient Assistance Programmes may also be excluded, but only where the order's conditions concerning undertakings, patient information and supporting records are met.
In the case of medicines that have been identified after 31st March 2026, the computation is done using the current PTS/PTD. In case the manufacturer distributes the medicine directly to a hospital or any medical institution, then such an institution will be considered as the stockist/distributor in computing the MRP.
These conditions may influence the final allowed price. Therefore, manufacturers need to look at the relevant sales arrangements rather than using the formula blindly.
For pharmaceutical manufacturers, an NPPA compliance checklist can help track price calculations, Annexure I submissions, Form V price lists and supporting records as part of a wider pharmaceutical compliance review.
Revised MRP Responsibilities for Chemists, Retailers and Hospitals
This is also going to impact those businesses that sell medicines to their customers directly. Starting from 9 November 2026, the pharmacist or the hospital pharmacy cannot charge more than the revised MRP of that formulation.
This rule is applicable regardless of the fact that the previous stock or bills contain a higher price. Firms are advised to compare the new price with the information in the product specifications, not just the old price list.
The NPPA order requires retailers, dealers, hospitals and institutions to display the applicable manufacturer-supplied price lists at their premises in a place accessible to consumers. Hospitals and medical institutions must also monitor the revised MRPs and prominently display the relevant information on their websites.
Businesses should also review how revised prices are reflected in invoices, procurement records and billing systems. These checks are sensible internal controls that can help avoid mistakes when selling affected medicines.
| Business type | Pricing compliance check | Useful supporting records |
| Manufacturer | Check covered formulations, permitted MRPs and required reporting | PTS/PTD records, Annexure I, Form V price lists |
| Distributor or stockist | Confirm prices against manufacturer-issued updates | Updated price lists and supply invoices |
| Chemist or retail pharmacy | Check that billed prices do not exceed the applicable revised MRP | Product details, sale bills and displayed price lists |
| Hospital or medical institution | Review patient billing and applicable price-display requirements | Price lists, procurement records and billing information |
This is a practical review table. The exact statutory duties depend on the business and the original NPPA order.
Impact of Anti-Cancer Medicine Price Reductions on Patients and Businesses
For patients, the biggest benefit is a lower maximum price for several medicines used in cancer care. The government reported that 679 brands had undergone MRP reductions exceeding 50%, with the highest reported decrease reaching 96.45%.
The annual savings made by consumers of 3,540.38 crore rupees show the possible financial impact of the intervention. It is only an estimate depending on the reduction in prices, and it does not mean that each consumer will be able to save the stated amount. The savings vary according to the drug prescribed, its brand, and the quantity and previous price.
For pharmaceutical companies, however, the effects are not limited to just the price of the drug. Consistency between the pricing calculations and the company’s communication with regulatory agencies is required. Price records of distributors may have to be revised, while pharmacies and hospitals should verify that the billing system contains the latest MRPs.
The trouble is that accurate pricing has to be maintained throughout the process of distribution. While the manufacturer has updated its price list, it would be of no use if the retailer is still charging the previous MRP.
How to Check the Revised MRP of Anti-Cancer Medicines Online
Consumers do not need to depend entirely on the price quoted by a pharmacy. The NPPA provides official medicine-price information through its website and Pharma Sahi Daam platform.
To verify the revised MRP:
- Visit the NPPA revised-price page or access the official Pharma Sahi Daam service.
- Find the relevant medicine using its name or other available product details.
- Check the brand, strength, dosage form and pack size.
- Compare the applicable revised MRP with the price charged.
- Retain the purchase bill and medicine-pack details if a possible overcharge is identified.
The correct product details matter. The MRP of one strength or brand cannot automatically be used to assess the price of another.
For anyone checking how to verify the revised MRP of anti-cancer medicines online, matching the exact formulation is more reliable than comparing only the drug name.
Revised price information from the NPPA will be updated as per the price reports of the manufacturers. Thus, firms should look at the most current records rather than depend on old price lists.
How to Report Overcharging of Anti-Cancer Medicines?
Patients or consumers who believe they have been charged above the applicable revised MRP can raise a complaint with NPPA.
The authority operates the Pharma Jan Samadhan grievance mechanism, which allows complaints relating to medicine prices and other specified pharmaceutical issues. This facility is integrated with the Pharma Sahi Daam platform.
Complaints may be made through the following channels:
- Online: Pharma Jan Samadhan / Pharma Sahi Daam
- Email: monitoring-nppa@gov.in
- NPPA helpline: 1800-11-1255
- Official website: https://nppa.gov.in/
Consumers are supposed to state the name of the medicine, brand, dosage, the company producing the medicine, and the cost involved. The bill of purchase and information on the pack will assist the regulatory body to investigate the case.
The complaint is reviewed according to the applicable procedures and legal provisions. Filing a complaint does not automatically establish that the seller has violated the pricing order.
NPPA Monitoring and Consequences of Non-Compliance
The revised pricing order provides for monitoring by NPPA and State Drug Controllers. Manufacturers, distributors, retailers, hospitals and medical institutions are required to assist the competent authorities in verifying compliance.
A manufacturer that fails to reduce prices as required may face recovery proceedings under DPCO 2013. The order also treats non-submission of prescribed revised price information as non-reduction of MRP for the purpose of initiating applicable recovery action.
Where overcharging is established, manufacturers may be liable to deposit the excess amount along with applicable interest under DPCO 2013 and the Essential Commodities Act, 1955.
The amount and nature of action depend on the relevant legal provisions and findings of the authority. The notification should not be interpreted as creating an automatic fixed penalty for every pricing error.
Accuracy in calculations, timely submission and proof of price communication are key for organizations. This documentation may assist in proving how the new MRP was arrived at.
What Pharmaceutical Businesses Should Do After the Revised MRP Notification
The revised prices have already taken effect. Businesses handling the identified medicines should therefore concentrate on confirming whether the new requirements have been implemented correctly.
The practical review must consist of the following:
- Identification of medicines: Matching the company's products to the 137 medicines mentioned in the NPPA notification.
- Confirmation of MRP limits: Checking relevant pricing calculations and official prices.
- Check regulatory reporting: Confirm whether Annexure I, Form V and relevant IPDMS requirements have been completed.
- Review price communication: Check whether distributors, retailers, hospitals and other relevant stakeholders have received the revised information.
- Consider the prevailing selling prices: Ensure that the prices being charged via pharmacies and hospitals do not go beyond the revised MRPs.
- Keep proper documentation: Retain all relevant calculations and communications regarding pricing.
- Monitor NPPA directions: Review subsequent amendments, updated price lists and clarifications when they are issued.
The exact responsibilities differ according to the business's role. A pharmaceutical manufacturer may have reporting and production obligations that do not apply in the same way to a retail chemist.
The objective of such a review must be to find the relevant duties and address any real gaps, not to generate more documentation or treat every internal recommendation as a legal obligation.
How Corpseed Can Help with Pharmaceutical Regulatory Compliance
The new MRP requirements of NPPA emphasize the need to ensure that the business activities of pharmaceuticals are consistent with the relevant regulatory requirements. In addition to medicine pricing, manufacturers, wholesalers, importers and retailers may have to be in compliance with drug licensing and other regulations.
Corpseed assists businesses with several pharmaceutical licensing and regulatory services. Depending on the nature of the business, the following services may be relevant:
- Drug License Registration: Assistance with applicable drug licensing requirements for eligible manufacturers, distributors and sellers.
- Drug Retail License: Guidance for pharmaceutical outlets interested in obtaining their required drug retail license.
- FDA Wholesale License: Help with the requirements for obtaining the wholesale drug license.
- CDSCO Registration: Support with relevant CDSCO registration, licensing and approval processes.
These services relate to the broader pharmaceutical regulatory framework. They do not replace the MRP calculations, price submissions or other responsibilities imposed by the NPPA order.
Businesses that need assistance with drug licensing or related pharmaceutical regulatory requirements can contact Corpseed to discuss the relevant services.
Businesses seeking pharmaceutical regulatory compliance services, drug licence consultancy or CDSCO registration assistance should choose support based on their actual licensing and compliance requirements.
Need assistance with pharmaceutical regulatory compliance?
Book a Free Consultation with Corpseed to understand the licensing and regulatory requirements applicable to your business.
Key Takeaways
The NPPA's revised MRPs for reported anti-cancer formulations took effect on 9 November 2026 under the Trade Margin Rationalisation order issued on 17 October 2026.
The order includes 137 identified non-scheduled drugs and restricts trade margins to 30%. As of 8 November 2026, 1,364 formulations of 121 drugs had new MRPs reported, resulting in savings of an estimated 3,540.38 crore rupees per year for consumers. Manufacturers must follow the applicable MRP calculation, reporting, price-publication and supply requirements. Retailers and hospital pharmacies must not charge more than the revised MRP. Affected businesses should check their products and pricing arrangements against the original order and current NPPA price records.
Schedule a Call Back
Document Preview
Embedded reference document
